New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia

Veterinary Clinics of North America - Small Animal Practice

Volumn 33, Issue 6, 2003, Pages 1317-1334

  Weiss, Douglas J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; AZACITIDINE; CAPTOPRIL; CEPHALOSPORIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA METHYLTRANSFERASE; DOXORUBICIN; ERYTHROPOIETIN; ESTROGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRISEOFULVIN; HYDROXYUREA; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHENOTHIAZINE; PROTEIN TYROSINE KINASE INHIBITOR; QUINIDINE; RAS PROTEIN; SULFADIAZINE; THALIDOMIDE; TOPOTECAN; TRANQUILIZER; UNINDEXED DRUG; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADIPOSE TISSUE; ANIMAL CARE; ARTICLE; BLOOD ANALYSIS; BONE MARROW; BONE MARROW APLASIA; BONE MARROW BIOPSY; BONE MARROW DISEASE; BONE MARROW HYPOPLASIA; CAT DISEASE; CHRONIC KIDNEY FAILURE; CYTOPENIA; DISEASE CLASSIFICATION; DISEASE COURSE; DOG DISEASE; DRUG EXPOSURE; EHRLICHIA; FELINE LEUKEMIA VIRUS; GENE MUTATION; HUMAN; IONIZING RADIATION; LEUKEMIA; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCYTOPENIA; PARVOVIRUS; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PROBABILITY; PROGNOSIS; SEPSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS; EHRLICHIA; FELIDAE; FELINE LEUKEMIA VIRUS; FELIS CATUS; PARVOVIRUS;

EID: 0347504486     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(03)00094-9     Document Type: Review

References (74)

1. Shelly SM. Causes of canine pancytopenia. Compend Contin Educ Prac Vet 1988;10: 9-17.
2. Weiss DJ. Detecting and diagnosing the cause of canine pancytopenia. Vet Med (Praha) 2002;97:21-32.
3. Blue JT. Myelodysplastic syndromes and myelofibrosis. In: Feldman BF, Zinkl JG, Jain NC, editors. Schalm's veterinary hematology. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 682-6.
4. Couto CG, Kallet AJ. Preleukemic syndrome in a dog. J Am Vet Med Assoc 1984;184:1389-92.
5. Weiss DJ, Raskin R, Zerbe C. Myelodysplastic syndrome in two dogs. J Am Vet Med Assoc 1985;187:1038-40.
6. Raskin RE, Krehbiel JD. Myelodysplastic changes in a cat with myclomonocytic leukemia. J Am Vet Med Assoc 1985;187:171-4.
7. Hisasue M, Okayama H, Okayama T, Suzuki T, Mizuno T, Fujino Y, et al. Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes. J Vet Med 2001;15:471-7.
8. Shimoda T, Shiranaga N, Mashita T, Hasegawa A. A hematologic study on thirteen cats with myelodysplastic syndrome. J Vet Med Sci 2000;62:59-64.
9. Weiss DJ, Christopher MM. Idiopathic aplastic anemia in the dog. Vet Clin Pathol 1985;14:23-5.
10. Steinberg S. Aplastic anemia in a dog. J Am Vet Med Assoc 1970;157:966-7.
11. Maschek H, Kaloutsi V, Rodriguez- Kaiser M. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993;66:117-22.
12. Weiss DJ, Aird B. Cytologic evaluation of primary and secondary myelodysplastic syndromes in the dog. Vet Clin Pathol 2001;30:67-75.
13. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ. Functional disturbances of the marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002;16:785-90.
14. List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002;7:39-49.
15. Weiss DJ, Smith SA. Primary myelodysplastic syndromes of dogs: a report of 12 cases. J Vet Intern Med 2000;14:491-4.
16. Vallespi T, Torrabadella M, Julia A, Irriguible D, Jaen A, Acebedo G, et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 1985;61:83-92.
17. Schuetz TJ, Stone RM. Myelodysplastic syndromes. In: Provan D, Gribben J, editors. Molecular hematology. 1st edition. New York: Blackwell Science; 2000. p. 75-84.
18. Tolle DV, Cullen SM, Seed TM, Fritz TE. Circulating micromegakaryocytes preceding leukemia in three dogs exposed to 2.5 Rad gamma radiation. Vet Pathol 1983;20:111-4.
19. Bennett M, Catovsky D, Daniel MT, Flandrin G, Dalton DAG, Granlnick HR, et al. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
20. Kouides PA, Bennett JH. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:485-98.
21. Jain NC, Blue JT, Grindem CB, Harvey JW, Kociba GJ, Krehbiel JD, et al. Proposed criteria for classification of acute myeloid leukemia in dogs and cats. Vet Clin Pathol 1991;20:63-82.
22. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposal for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983-92.
23. Raskin RE. Myelopoiesis and myeloproliferative disorders. Vet Clin North Am Small Anim Pract 1996;26:1023-42.
24. Boone L, Knauer K, Rapp SW, Stewart JF, Modiano JF. Use of human recombinant erythropoietin and prednisolone for treatment of myelodysplastic syndrome with erythroid predominance in a dog. J Am Vet Med Assoc 1998;213:999-1001.
25. Hisasue M, Nishigaki K, Katae H, Yuri K, Mizuno T, Fujino Y, et al. Clonality analysis of various hematopoietic disorders in cats naturally infected with feline leukemia virus. J Vet Med Sci 2000;62:1059-65.
26. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002;26:677-86.
27. Merchav S, Wagemaker G, Sousa LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 1991;5:340-6.
28. + human marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-90.
29. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al. A role for tumor necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-88.
30. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguien F, Melle J, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11:839-45.
31. Dansey R. Myelodysplasia. Curr Opin Oncol 2000;12:13-21.
32. Belamy WT, Richter L, Sirjani D. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-34.
33. Deldar A, Lewis H, Bloom J, Weiss L. Cephalosporin-induced changes in the ultrastructure of canine bone marrow. Vet Pathol 1988;25:211-8.
34. Allerman AR, Harvey JW. The morphologic effects of vincristine sulfate on canine bone marrow cells. Vet Clin Pathol 1993;22:36-41.
35. Harvey JW, Wlofsheimer KJ, Simpson CF, Frenck TW. Pathologic sideroblasts and siderocytes associated with chloramphenicol therapy in a dog. Vet Clin Pathol 1994; 24:36-42.
36. Meischer PA, Farve H, Beris P. Autoimmune myelodysplasia. Semin Hematol 1991;28:322-30.
37. Michels SD, McKenna RW, Arthur DC. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985;65:1364-72.
38. Rubin CM, Arthur DC, Woods WG, Lange BJ, Nowell PC, Rowley JD, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood 1991;78:2982-8.
39. Weiss DJ, Reidarson TH. Idiopathic dyserythropoiesis in a dog. Vet Clin Pathol 1989;18:43-6.
40. Miyamoto T, Horie T, Shamada T, Kuwamura M, Baba E. Long-term case study of myelodysplastic syndrome in a dog. J Am Anim Hosp Assoc 1999;35:475-81.
41. Canfield PJ, Watson ADJ, Ratcliffe RCC. Dyserythropoiesis, sideroblasts/siderocytes and hemoglobin crystals. Vet Clin Pathol 1987;16:21-8.
42. Weiss DJ, Lulich J. Myelodysplastic syndrome with sideroblastic differentiation in a dog. Vet Clin Pathol 1999;28:59-63.
43. Lindberg EH, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001;112:714-26.
44. McManus PM, Hess RS. Myelodysplastic changes in a dogs with subsequent acute myeloid leukemia. Vet Clin Pathol 1998;27:112-5.
45. Harvey JW, French TW, Meyer DJ. Chronic iron deficiency anemia in dogs. J Am Anim Hosp Assoc 1982;18:946-60.
46. George JW, Duncan JR. The hematology of lead poisoning in man and animals. Vet Clin Pathol 1979;8:23-30.
47. Thenen SW, Rassmussen KM. Megaloblastic erythropoiesis and tissue depletion of folic acid in the cat. Am J Vet Res 1978;39:1205-7.
48. Cummins JM, Tompkins MF, Olsen RG. Oral use of human interferon alpha in cats. J Biol Resp Mod 1988;7:513-6.
49. Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W. Risk assessment in primary myelodysplastic syndromes: validation of the Dusseldorf score. Leukemia 1994;8:1906-13.
50. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
51. Tassin F, Dewe W, Schaaf N, Herens C, Ravoet C, Albert A, et al. A four-part parameter index of marrow dysplasia had predictive value for survival in myelodysplastic syndromes. Leuk Lymphoma 2000;36:485-96.
52. Akashi K, Eto T, Shinuya T, Shimoda K, Harada M, Niho Y. Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor. Leuk Res 2000;24:243-8.
53. Gaenser A, Karthous M. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Leuk Lymphoma 1997;26:13-27.
54. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F. Thalidomide produces transfusion independence in long-standing refractory anemia of patients with myelodysplastic syndromes. Blood 2001;98:958-65.
55. Silverman LR, Demakos EP, Peterson B. A randomized controlled trial of subcutaneous azacitidine (AZA C) in patients with the myelodysplastic syndrome (MDS): a study of the cancer and leukemia group B (CALGB) [abstract]. J Clin Oncol 1998;17:14.
56. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996;23: 58-63.
57. Beran M, Estey E, O'Brein SM, Giles JF, Kollen CA, Kornblau S, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 1998;31:521-31.
58. Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 2000; 85:1002-3.
59. Weiss DJ, Armstrong PJ. Nonregenerative anemias in the dog. Compend Contin Educ Pract Vet 1984;6:452-60.
60. Scopes J, Daly S, Atkinson R, Ball SE, Gordonsmith EC. Aplastic anemia evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony-stimulating factor in vitro. Blood 1996;87:3179-85.
61. Hus HC, Tsai WH, Chen LY, Hsu ML, Ho BCHH, Lin CK. Production of hematopoietic regulatory cytokines by peripheral blood mononuclear cells in patients with aplastic anemia. Exp Hematol 1996;24:31-6.
62. Boosinger TR, Rebar AH, DeNicola DB, Boon GD. Bone marrow alterations associated with canine parvoviral enteritis. Vet Pathol 1982;19:558-61.
63. Dornsife RE, Gasper PW, Mullins JI, Hoover EA. Induction of aplastic anemia by intrabone marrow inoculation of molecularly cloned feline retrovirus. Leukemia Res 1989; 13:745-55.
64. Kuehn NF, Gaunt SD. Clinical and hematologic findings in canine ehrlichiosis. J Am Vet Med Assoc 1985;186:355-8.
65. Peavy GM, Holland CJ, Dutta SK, Smith G, Moore A, Rich LJ, et al. Suspected ehrlichial infection in five cats from a household. J Am Vet Med Assoc 1997;210:231-4.
66. Bond VP, Cronkite EP. Effects of radiation on mammals. Annual Rev Physiol 1957;19: 299-328.
67. Weiss DJ, Klausner JS. Drug-associated aplastic anemia in dogs: eight cases (1984-1988). J Am Vet Med Assoc 1990;196:472-9.
68. Weiss DJ. Leukocyte response to toxic injury. Toxicol Pathol 1993;21:135-40.
69. Sherding RG, Wilson GP, Kociba GJ. Bone marrow hypoplasia in eight dogs with Sertoli cells tumors. J Am Vet Med Assoc 1981;178:497-501.
70. Alleman AR, Harvey JW. The morphologic effects of vincristine sulfate on canine bone marrow cells. Vet Clin Pathol 1993;22:36-41.
71. Couto CG. Toxicity of anticancer chemotherapy. In: Campfield WW, editor. Kal Kan symposium for the treatment of small animal diseases. Vermon, CA: Kal Kan Pet Foods; 1986. p. 37-43.
72. Walker D, Cowell RL, Clinkenbeard KD, Feder B, Meinkoth JH. Bone marrow mast cell hyperplasia in dogs with aplastic anemia. Vet Clin Pathol 1997;26:106-11.
73. Shadduck RK. Aplastic anemia. In: Beutler E, Lichtman MA, Collier BS, Kipps TJ, editors. William's hematology. 5th edition. New York: McGraw-Hill; 1995. p. 238-51.
74. Harris CK, Gasper PW. Bone marrow transplantation in the dog. Compend Contin Educ Pract Vet 1986;8:337-45.